Go Back

Company or ticker...

Enliven Therapeutics

Enliven develops small molecule cancer drugs focused on genetically defined tumors.

Ticker

M. Cap

PS

PE

YTD

10MA

20MA

50MA

200MA

ELVN

4.2B

0.0

n/a

274.84%

Key Facts

M. Cap

PS

PE

YTD

4.2B

0.0

n/a

274.84%

10MA

20MA

50MA

200MA

$ELVN

The Fullstack Investor

by Lin

v1.3

Join Now

Join Now

The Fullstack Investor

by Lin

v1.3

Join Now

Join Now

Join Now

Join Now